Health Care & Life Sciences » Pharmaceuticals | Paratek Pharmaceuticals Inc.

Paratek Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,747.00
4,342.00
-
29.00
12,616.00
17,117
Cost of Goods Sold (COGS) incl. D&A
-
-
714.00
-
-
-
Gross Income
-
-
714.00
-
-
-
SG&A Expense
24,966.00
10,642.00
70,039.00
107,557.00
96,337.00
120,533
EBIT
23,309.00
6,520.00
70,753.00
-
84,421.00
104,049
Unusual Expense
2,962.00
10,418.00
700.00
345.00
159.00
36
Non Operating Income/Expense
75.00
179.00
37.00
4.00
34.00
44
Interest Expense
-
718.00
770.00
3,223.00
5,079.00
10,985
Pretax Income
27,446.00
17,835.00
70,860.00
111,636.00
88,316.00
111,854
Income Tax
-
-
-
-
753.00
502
Consolidated Net Income
27,446.00
17,835.00
70,860.00
111,636.00
89,069.00
112,356
Net Income
27,446.00
17,835.00
70,860.00
111,636.00
89,069.00
112,356
Net Income After Extraordinaries
27,446.00
17,835.00
70,860.00
111,636.00
89,069.00
112,356
Net Income Available to Common
27,446.00
19,762.00
70,860.00
111,636.00
89,069.00
112,356
EPS (Basic)
17.52
7.82
4.29
5.51
3.32
3.57
Basic Shares Outstanding
1,564.30
2,528.60
16,501.90
20,253.10
26,827.30
31,513.50
EPS (Diluted)
17.54
7.82
4.29
5.51
3.32
3.57
Diluted Shares Outstanding
1,564.30
2,528.60
16,501.90
20,253.10
26,827.30
31,513.50
EBITDA
23,219.00
6,300.00
70,039.00
107,528.00
83,721.00
103,416
Non-Operating Interest Income
-
-
-
1,069.00
1,377.00
3,260
Preferred Dividends
-
1,927.00
-
-
-
-

About Paratek Pharmaceuticals

View Profile
Address
75 Park Plaza
Boston Massachusetts 02116
United States
Employees -
Website http://www.paratekpharma.com
Updated 07/08/2019
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include Omadacycline and Sarecycline, which are used for the treatment of serious community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, and urinary tract infections. The company was founded in February 2001 and is headquartered in Boston, MA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.